|MDACC Study No:||2011-0951 (clinicaltrials.gov NCT No: NCT01357161)|
|Title:||A Randomized, Phase II Study Evaluating MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Cancer|
|Principal Investigator:||Robert Coleman|
|Treatment Agent:||Carboplatin; MK-1775; Paclitaxel|
|Study Description:||The goal of this clinical research study is to compare MK-1775 in combination |
with paclitaxel and carboplatin to placebo in combination with paclitaxel and
carboplatin in patients with ovarian cancer. Researchers want to learn if
adding MK-1775 can help to control the disease. The safety of this drug
combination will also be studied.
MK-1775 is designed to stop cancer cells from repairing themselves, which may
cause the cancer cells to die.
Paclitaxel and carboplatin are designed to block cancer cells from dividing,
which may cause them to die.
A placebo is not a drug. It looks like the study drug but is not designed to
treat any disease or illness. It is designed to be compared with a study drug
to learn if the study drug has any real effect.